<DOC>
	<DOCNO>NCT02578277</DOCNO>
	<brief_summary>The purpose study study effect BMS-955176 single-dose PK parameter probe substrate caffeine , metoprolol , montelukast , flurbiprofen , omeprazole , midazolam , digoxin , pravastatin</brief_summary>
	<brief_title>Study Effects BMS-955176 Pharmacokinetics Probe Substrates</brief_title>
	<detailed_description />
	<criteria>1 . Written Informed Consent 2 . Healthy male female ( childbearing potential ) subject determine medical history , surgical history , physical examination , vital sign , ECGs , clinical laboratory determination 3 . Body mass index ( BMI ) 18.0 kg/m2 32.0 kg/m2 , inclusive , screen Day 1 . BMI = weight ( kg ) / [ height ( ) ] 4 . Women must document proof childbearing potential ( eg , surgically sterile , postmenopausal document folliclestimulating hormone ( FSH ) &gt; 40 mIU/mL ) breast feed 5 . Males sexually active WOCBP must agree follow instruction method ( ) contraception duration treatment BMS955176 addition posttreatment completion period 1 . Any significant acute chronic medical illness 2 . Use tobacco , excessive alcohol 3 . Medical history indicative increase risk cardiac arrhythmia cardiac disease history asthma , bronchospasm , sleep apnea , rhabdomyolysis , bleed disorder , major depressive disorder within past 6 month , peptic ulcer significant GI bleed , Raynaud 's disease , gastrointestinal surgery could impact upon absorption study drug 4 . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG , clinical laboratory determination beyond consistent target population 5 . History allergy BMS955176 , digoxin ( member digitalis glycoside class drug ) , caffeine , metoprolol , montelukast , flurbiprofen , omeprazole , midazolam , pravastatin , related compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>